Old Web
English
Sign In
Acemap
>
authorDetail
>
Peter Koelblinger
Peter Koelblinger
Paracelsus Private Medical University of Salzburg
Medicine
Melanoma
Adverse effect
Cohort
Internal medicine
4
Papers
4
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Adjuvant anti-PD-1 antibody treatment in stage III/IV melanoma: real-world experience and health economic considerations
2021
Journal Der Deutschen Dermatologischen Gesellschaft
Peter Koelblinger
Magdalena Hoellwerth
Marie-Therese Dernoscheg
Lukas Koch
Erika Richtig
Marina Wanner
Van Anh Nguyen
Herwig Ostermann
Johann W Bauer
Martin Laimer
Show All
Source
Cite
Save
Citations (0)
Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany.
2021
Journal for ImmunoTherapy of Cancer
Julia Maria Ressler
Matthias Karasek
Lukas Koch
Rita Silmbrod
Joanna Mangana
Sofiya Latifyan
Veronica Aedo-Lopez
Helmut Kehrer
Felix Weihsengruber
Peter Koelblinger
Christian Posch
Julian Kofler
Olivier Michielin
Erika Richtig
Christine Hafner
Christoph Hoeller
Show All
Source
Cite
Save
Citations (4)
Adjuvante Anti-PD-1-Antikörpertherapie bei Stadium-III/IV-Melanom: Anwendungsdaten aus der klinischen Routine und gesundheitsökonomische Aspekte
2021
Journal Der Deutschen Dermatologischen Gesellschaft
Peter Koelblinger
Magdalena Hoellwerth
Marie-Therese Dernoscheg
Lukas Koch
Erika Richtig
Marina Wanner
Van Anh Nguyen
Herwig Ostermann
Johann W Bauer
Martin Laimer
Show All
Source
Cite
Save
Citations (0)
Covid‐19‐induced reduction in primary melanoma diagnoses: Experience from a dermatopathology referral center
2021
Journal of Clinical Medicine
Magdalena Hoellwerth
Andreas Kaiser
Michael Emberger
Matthias Brandlmaier
Martin Laimer
Alexander Egger
Johann W Bauer
Peter Koelblinger
Show All
Source
Cite
Save
Citations (0)
1